Review explores CD33 isoforms' roles in microglial dysfunction and therapeutic strategies in Alzheimer's disease, suggesting implications for treatment.
Key Points
This review aims to dissect the splicing dysregulation of CD33 isoforms and their impact on microglial dysfunction in Alzheimer's disease.
Analysis of CD33 isoforms CD33M and CD33m in relation to microglial activity and neuroinflammation.
Examination of genetic polymorphisms and splicing regulation by specific proteins.
Evaluation of therapeutic strategies targeting CD33, including immunotherapies and splicing modulators.
CD33M isoform is pro-pathogenic, while CD33m is protective, influencing Aβ clearance.
CD33 and TREM2 interplay affects DAP12 signaling pathways.
Emerging therapies face challenges in brain barrier penetration and specificity.